Abstract
The development of Parkinson’s disease (PD) has a substantial genetic basis. Variants in the PRKN gene account for roughly half of autosomal-recessive PD cases, yet most variants remain classified as variants of uncertain significance. PRKN encodes the E3 ubiquitin-protein ligase, Parkin, that plays a key role in mitochondrial quality control by initiating mitophagy. In this work, we introduce a multiplexed mitophagy assay and measure the activity of more than 99% of all possible single–amino acid substitution and nonsense variants of Parkin. We also demonstrate that misfolded, rapidly degraded variants autonomously trigger Parkin-independent mitophagy. The obtained activity landscape closely reflects known structural and functional aspects of Parkin while revealing new insights into specific functional effects across the protein. This dataset near-perfectly distinguishes pathogenic from benign variants and surpasses both computational predictors and abundance-based metrics in pathogenicity assessment. Finally, the data pinpoint hypomorphic variants that could be amenable to rescue in future personalized therapeutic approaches for PD.
Full text
2,357 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
The development of Parkinson’s disease (PD) has a substantial genetic basis. Variants in the PRKN gene account for roughly half of autosomal-recessive PD cases, yet most variants remain classified as variants of uncertain significance. PRKN encodes the E3 ubiquitin-protein ligase, Parkin, that plays a key role in mitochondrial quality control by initiating mitophagy. In this work, we introduce a multiplexed mitophagy assay and measure the activity of more than 99% of all possible single–amino acid substitution and nonsense variants of Parkin. We also demonstrate that misfolded, rapidly degraded variants autonomously trigger Parkin-independent mitophagy. The obtained activity landscape closely reflects known structural and functional aspects of Parkin while revealing new insights into specific functional effects across the protein. This dataset near-perfectly distinguishes pathogenic from benign variants and surpasses both computational predictors and abundance-based metrics in pathogenicity assessment. Finally, the data pinpoint hypomorphic variants that could be amenable to rescue in future personalized therapeutic approaches for PD.
Competing Interest Statement
K.L.-L. holds stock options in, receives sponsored research from, and is a consultant for Peptone Ltd. The remaining authors have no relevant financial or non-financial interests to disclose.
- Abbreviations
- ACT
- activation element
- AO
- antimycin and oligomycin
- AM
- AlphaMissense
- ARPD
- autosomal-recessive Parkinson’s disease
- AUC
- area under the curve
- Baf
- Bafilomycin
- DMEM
- Dulbecco’s modified Eagle medium
- Dox
- doxycycline
- DUBTAC
- deubiquitylating targeted chimeras
- FACS
- fluorescence-activated cell sorting
- FBS
- fetal bovine serum
- IBR
- in-between RING
- IQR
- interquartile range
- IRES
- internal ribosomal entry site
- MAGIC
- mitochondria as guardian in cytosol
- MAVE
- multiplexed assay of variant effects
- MED
- median
- OMM
- outer mitochondrial membrane
- PAP
- peptide abundance predictor
- PD
- Parkinson’s disease
- REP
- Repressor element
- ROC
- Receiver Operating Characteristic
- SD
- standard deviation
- pUb
- phospho-ubiquitin
- pUBL
- phospho-UBL
- Ub
- ubiquitin
- UBL
- ubiquitin-like
- VAMP-seq
- variant abundance by massively parallel sequencing
- VUS
- variant of unknown significance
- WT
- wild-type.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.